These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8334997)

  • 1. Hormone-conditional transformation by fusion proteins of c-Abl and its transforming variants.
    Jackson P; Baltimore D; Picard D
    EMBO J; 1993 Jul; 12(7):2809-19. PubMed ID: 8334997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization.
    Smith KM; Van Etten RA
    J Biol Chem; 2001 Jun; 276(26):24372-9. PubMed ID: 11320088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase.
    Mayer BJ; Baltimore D
    Mol Cell Biol; 1994 May; 14(5):2883-94. PubMed ID: 8164650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites.
    Ren R; Ye ZS; Baltimore D
    Genes Dev; 1994 Apr; 8(7):783-95. PubMed ID: 7926767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct analysis of the binding of the abl Src homology 2 domain to the activated epidermal growth factor receptor.
    Zhu G; Decker SJ; Mayer BJ; Saltiel AR
    J Biol Chem; 1993 Jan; 268(3):1775-9. PubMed ID: 7678409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl.
    Jackson PK; Paskind M; Baltimore D
    Oncogene; 1993 Jul; 8(7):1943-56. PubMed ID: 8510937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro.
    Van Etten RA; Debnath J; Zhou H; Casasnovas JM
    Oncogene; 1995 May; 10(10):1977-88. PubMed ID: 7539119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth inhibition by Abl requires an interplay of its SH2 and tyrosine kinase domains.
    Mattioni T; Mayer BJ; Picard D
    FEBS Lett; 1996 Jul; 390(2):170-4. PubMed ID: 8706852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells.
    Sirvent A; Boureux A; Simon V; Leroy C; Roche S
    Oncogene; 2007 Nov; 26(52):7313-23. PubMed ID: 17533370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that SH2 domains promote processive phosphorylation by protein-tyrosine kinases.
    Mayer BJ; Hirai H; Sakai R
    Curr Biol; 1995 Mar; 5(3):296-305. PubMed ID: 7780740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain.
    Mysliwiec T; Perego R; Kruh GD
    Oncogene; 1996 Feb; 12(3):631-40. PubMed ID: 8637720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase.
    Muller AJ; Pendergast AM; Parmar K; Havlik MH; Rosenberg N; Witte ON
    Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3457-61. PubMed ID: 7682703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain.
    Brasher BB; Roumiantsev S; Van Etten RA
    Oncogene; 2001 Nov; 20(53):7744-52. PubMed ID: 11753652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias.
    McWhirter JR; Wang JY
    EMBO J; 1993 Apr; 12(4):1533-46. PubMed ID: 8467803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An intramolecular SH3-domain interaction regulates c-Abl activity.
    Barilá D; Superti-Furga G
    Nat Genet; 1998 Mar; 18(3):280-2. PubMed ID: 9500553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a protein that binds to the SH3 region of Abl and is similar to Bcr and GAP-rho.
    Cicchetti P; Mayer BJ; Thiel G; Baltimore D
    Science; 1992 Aug; 257(5071):803-6. PubMed ID: 1379745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a novel member of the DOK family that binds and modulates Abl signaling.
    Cong F; Yuan B; Goff SP
    Mol Cell Biol; 1999 Dec; 19(12):8314-25. PubMed ID: 10567556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human raf-1 protein kinase.
    Samuels ML; Weber MJ; Bishop JM; McMahon M
    Mol Cell Biol; 1993 Oct; 13(10):6241-52. PubMed ID: 8413224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation of Dok1 by Abl family kinases inhibits CrkI transforming activity.
    Ng KY; Yin T; Machida K; Wu YI; Mayer BJ
    Oncogene; 2015 May; 34(20):2650-9. PubMed ID: 25043303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.
    Ling X; Ma G; Sun T; Liu J; Arlinghaus RB
    Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.